Navigation Links
Vaccinex Antibody Licensed to GlaxoSmithKline
Date:2/15/2008

ROCHESTER, N.Y., Feb. 15 /PRNewswire/ -- EUSA Pharma (Oxford, UK), a Vaccinex collaboration partner, has announced that it has licensed OP-R003, a human anti-interleukin-6 antibody discovered by Vaccinex, to GlaxoSmithKline.

According to the terms of the product license, GSK will pay an up-front license fee, development milestones, and royalties on product sales to acquire the exclusive world-wide rights to develop and commercialize OP-R003 for the treatment of rheumatoid arthritis and other disease indications. Vaccinex will share 50% of fees, payments and royalties. The antibody was discovered by Vaccinex utilizing its ActivMAb(R) antibody discovery technology and first licensed for co-development by EUSA Pharma (formerly OPi SA).

"We are pleased that our collaboration in the discovery and co-development of OP-R003 has attracted such a world-class partner as GSK. Together with previously announced antibody partnerships with Biocon, Ltd. and Teva Pharmaceutical, this transaction further validates the quality of human antibodies selected with Vaccinex's ActivMAb(R) antibody discovery technology," remarked Dr. Maurice Zauderer, Vaccinex's President and CEO.

Commenting on the acquisition, Brian McVeigh, GSK's Worldwide Business Development Director of M&A Strategy and Transactions, said, "Interleukin-6 is increasingly recognized as an important biological target in a range of diseases, and consequently OP-R003 has great potential to meet a number of unmet medical needs."

About Vaccinex

Vaccinex, Inc. is a biotechnology company engaged in the discovery and development of human monoclonal antibodies and other biologics to treat a variety of serious illnesses, including autoimmune disease, inflammation, multiple sclerosis, and cancer. The company's patented ActivMAb(R) technology allows for the direct selection of high affinity, fully human monoclonal antibodies that would be difficult or impossible to identify using other systems. Vaccinex, on its own or with its partners, has advanced several antibodies from discovery and lead validation into IND-directed pre-clinical drug development. The company is headquartered in Rochester, NY, USA. For more information, please visit http://www.vaccinex.com.

Press Contact

Raymond E. Watkins, Vice President of Operations & Officer

Vaccinex, Inc.

+1.585.271.2700 Ext. 105

E-mail: rwatkins@vaccinex.com


'/>"/>
SOURCE Vaccinex, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Vaccinex, Inc. Announces Award of Key Patent in Europe for its Antibody Discovery Technology (ActivMab(R))
2. ARIUS presents new findings showing therapeutic antibody inhibits human leukemic cancer stem cells
3. Human Genome Sciences and Xencor Announce Antibody Collaboration
4. Laureate Announces Manufacturing Agreement with ARIUS for Trop-2 Targeting Antibody
5. ARIUS announces manufacturing Agreement with Laureate Pharma For Trop-2 targeting antibody
6. Roche Files IND for Second Genmab Antibody
7. Genmab A/S - R1507 Antibody to Enter Phase II Study to Treat Sarcoma
8. Fourth Genmab Antibody Developed Under Roche Collaboration to Enter Clinic
9. ARIUS announces manufacturing agreement with Avid Bioservices for CD44 Cancer Stem Cell antibody
10. Antibody Engineering Company f-star Raises EUR 3.0 Million in a Second Closing of its Series A Financing Round From Novo A/S
11. AstraZeneca Bolsters Its Worldwide Biologics Division Through Integration of Cambridge Antibody Technology Into MedImmune
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/29/2016)... CO (PRWEB) , ... April 29, 2016 , ... ... addressing the necessary fundamentals to transform technology into a viable company, CereScan’s CEO, ... growth. Mr. Kelley, a recognized leader and mentor in the Denver area ...
(Date:4/29/2016)... ... ... Intelligent Implant Systems announced today that the two-level components for the Revolution™ Spinal System ... These components expand the capabilities of the system and allow Revolution™ to be utilized ... the company has seen significant sales growth in 1Q 2016, and the system is ...
(Date:4/28/2016)... , April 28, 2016 The ... and Brayton Cryocoolers), Service (Technical Support, Product Repairs & ... - Global Forecast to 2022", published by MarketsandMarkets, the ... Billion by 2022, at a CAGR of 7.29% between ... data Tables and 94 Figures spread through 159 Pages ...
(Date:4/28/2016)... Hill, Conn. (PRWEB) , ... April 28, 2016 ... ... of financing and ongoing support for Connecticut's innovative, growing companies, today announced the ... digital health and financial technology (fintech) companies. , “VentureClash looks to ...
Breaking Biology Technology:
(Date:3/9/2016)... 9, 2016  Crossmatch ® , a leading ... today announced the addition of smart features to ... multi-factor authentication platform. New contextual and application-specific authentication ... security where it,s needed most — while minimizing ... . --> Washington, DC ...
(Date:3/3/2016)...  FlexTech, a SEMI Strategic Association Partner, awarded five ... Development, Leadership in Education, and, in a category new ... year of the FLEXI Awards and the winners ... past years . Judging was done on a ... criteria, by a panel of non-affiliated, independent, industry experts. ...
(Date:3/3/2016)... and DE SOTO, Kansas , ... Stroke Detection Plus® to offer Oncimmune,s Early CDT®-Lung, ... and early detection of lung cancer Early ... unions and individuals. --> Early CDT®-Lung test ... individuals. --> Oncimmune, a leader in early ...
Breaking Biology News(10 mins):